NCT04145570 2019-10-30
A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions
Quadras Scientific Solutions
Phase 4 Completed
Clinical Trials
9 trialsNCT00949910 2016-10-05
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 4 Completed
NCT01066884 2016-08-24
A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 4 Completed
NCT01402089 2016-02-02
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Cantonal Hospital of St. Gallen
Phase 4 Completed
NCT01609543 2016-02-01
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
Hoffmann-La Roche
Phase 4 Completed
NCT02000531 2016-01-13
Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population
Hoffmann-La Roche
Phase 4 Completed
NCT01196078 2015-07-27
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 4 Completed
NCT01287754 2015-06-02
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
Hoffmann-La Roche
Phase 4 Completed
NCT01230710 2015-03-30
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
Hoffmann-La Roche
Phase 4 Completed